Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 199-206

  Stephens, J W ^a   Bodvarsdottir, T B ^b   Wareham, K ^c   Prior, S L ^a   Bracken, R M ^a   Lowe, G D ^d   Rumley, A ^d   Dunseath, G ^a   Luzio, S ^a   Deacon, C F ^e   Holst, J J ^e   Bain, S C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c MORRISTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetes; GIP; Glibenclamide; GLP 1; Insulin; Oxidative stress; Repaglinide

Indexed keywords

ANTIOXIDANT; C PEPTIDE; CELL ADHESION MOLECULE; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; METFORMIN; REPAGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DRUG RESPONSE; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; E-SELECTIN; F2-ISOPROSTANES; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; PIPERIDINES; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME; WALES;

EID: 81255157890     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.014     Document Type: Article

References (33)

1. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.
2. de Vegt F., Dekker J.M., Ruhe H.G., Stehouwer C.D., Nijpels G., Bouter L.M., et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42:926-931.
3. Donahue R.P., Abbott R.D., Reed D.M., Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987, 36:689-692.
4. Lowe L.P., Liu K., Greenland P., Metzger B.E., Dyer A.R., Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997, 20:163-169.
5. Bonora E., Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001, 44:2107-2114.
6. Gin H., Rigalleau V. Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes. Diabetes Metab 2000, 26:265-272.
7. Efendic S., Portwood N. Overview of incretin hormones. Horm Metab Res 2004, 36:742-746.
8. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498.
9. Ban K., Noyan-Ashraf M., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
10. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
11. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
12. Ding X., Saxena N.K., Lin S., Gupta N., Anania F.A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
13. Gumieniczek A. Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment. Life Sci 2005, 78:259-263.
14. Gumieniczek A., Hopkala H., Rolinski J., Bojarska-Junak A. Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacol Res 2005, 52:162-166.
15. Manzella D., Grella R., Abbatecola A.M., Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005, 28:366-371.
16. Tankova T., Koev D., Dakovska L., Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2003, 59:43-49.
17. Mehrotra S., Ling K.L., Bekele Y., Gerbino E., Earle K.A. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet Med 2001, 18:109-115.
18. Wolever T.M., Chiasson J.L., Csima A., Hunt J.A., Palmason C., Ross S.A., et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75g oral glucose. Diabetes Care 1998, 21:336-340.
19. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
20. Krarup T., Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984, 9:35-46.
21. Sampson M.J., Gopaul N., Davies I.R., Hughes D.A., Carrier M.J. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 2002, 25:537-541.
22. Stephens J.W., Khanolkar M.P., Bain S.C. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 2009, 202:321-329.
23. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., Fowkes F.G. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005, 112:976-983.
24. Li Y., Xu L., Shen J., Ran J., Zhang Y., Wang M., et al. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes Res Clin Pract 2010, 88:42-47.
25. Hollingdal M., Sturis J., Gall M.A., Damsbo P., Pincus S., Veldhuis J.D., et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet Med 2005, 22:1408-1413.
26. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
27. Pratley R.E., Foley J.E., Dunning B.E. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiological approach to improve glucose control. Curr Pharm Des 2001, 7:1375-1397.
28. Hojberg P.V., Vilsboll T., Rabol R., Knop F.K., Bache M., Krarup T., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207.
29. Knop F.K., Vilsboll T., Hojberg P.V., Larsen S., Madsbad S., Volund A., et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes 2007, 56:1951-1959.
30. Chakraborty A., Chowdhury S., Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011, 93:56-62.
31. Matsumoto T., Noguchi E., Ishida K., Kobayashi T., Yamada N., Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008, 295:H1165-H1176.
32. Lund S.S., Tarnow L., Stehouwer C.D., Schalkwijk C.G., Teerlink T., Gram J., et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008, 158:631-641.
33. Schmoelzer I., Wascher T.C. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006, 5:9.